Corresponding Author: Mandar Jog, MD, Movement Disorder Centre, London Health Sciences Centre, The University of Western Ontario, 339 Windermere Rd, London, ON N6A 5A5, Canada (mandar.jog@lhsc.on.ca).
Published Online: November 7, 2022. doi:10.1001/jamaneurol.2022.3791
Conflict of Interest Disclosures: Dr Tuesta Bernaola reported fellowship funding from the Parkinson Society of Southwestern Ontario. Dr Ganguly reported grants and fellowship funding from the Academic Medical Organization of Southwestern Ontario. No other disclosures were reported. Dr Jog reported speaker’s fees and research funding from Allergan, AbbVie, Merz Pharmaceuticals, Boston Scientific, Valeo Pharma, Sunovion, and Paladin Labs and grants from Parkinson Society of Canada, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Mathematics of Information Technology and Complex Systems, the Research Council of Norway, Parkinson Society of Southwestern Ontario, Dystonia Medical Research Foundation, and Academic Medical Organization of Southwestern Ontario. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
2.Indelicato
E , Nachbauer
W , Eigentler
A ,
et al; EFACTS (European Friedreich’s Ataxia Consortium for Translational Studies). Onset features and time to diagnosis in Friedreich’s ataxia.
Orphanet J Rare Dis. 2020;15(1):198. doi:
10.1186/s13023-020-01475-9PubMedGoogle ScholarCrossref 5.Cabal-Herrera
AM , Tassanakijpanich
N , Salcedo-Arellano
MJ , Hagerman
RJ . Fragile X–associated tremor/ataxia syndrome (FXTAS): pathophysiology and clinical implications.
Int J Mol Sci. 2020;21(12):4391. doi:
10.3390/ijms21124391PubMedGoogle ScholarCrossref